 |
 |
|
|
|
| Ursodeoxycholic Acid |
 |
| 7beta-5beta cholestane - 24 - acid |
 |
| 128-13-2 |
 |
Content: Ursodeoxycholic acid in human bile in gallbladder accounted for a few. After oral administration of ursodeoxycholic acid, through the inhibition of cholesterol in the intestine reabsorption and lower cholesterol to bile secretion, and thereby reduces biliary cholesterol saturation. May be due to cholesterol dispersion and liquid crystal formation, and the cholesterol gallstones gradually dissolve. On the basis of the existing knowledge, ursodeoxycholic acid capsules for treatment of liver and bile stasis disease is mainly based on the hydrophilic, have a cytoprotective effect and no cell toxicity of ursodeoxycholic acid relative to alternative lipophilic, decontamination agent kind on the toxicity of bile acids, and promote liver cell secretion function and immune regulation to accomplish the.
Physical Character: This medicine can promote endogenous bile acid secretion, reduce reabsorption
antagonistic hydrophobic bile acid cytotoxicity, protecting liver cell membrane
dissolving cholesterol calculus
and to have immunomodulatory effects
Melting point: 200 ў¦204ЎЙ
|
 |
Alias: 3alpha, 7beta-5beta cholestane - 24 - acid
CAS No.: 128-13-2
MF: C24H40O4
MW: 392.58
Packing detail: 1KG / aluminum foil bag
|
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
